Skip to main content

Medical Oncology

Ausgabe 9/2023

Inhalt (30 Artikel)

Original Paper

Inhibition of IRE1 RNase activity modulates tumor cell progression and enhances the response to chemotherapy in colorectal cancer

Sana Abbasi, Helia Rivand, Fatemeh Eshaghi, Mohammad Amin Moosavi, Saeid Amanpour, Michael F. McDermott, Marveh Rahmati

Original Paper

SETD2 controls m6A modification of transcriptome and regulates the molecular oncogenesis of glioma

Subhadra Kumari, Mandakini Singh, Santosh Kumar, Srinivasan Muthuswamy

Original Paper

Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinoma

Wenbin Liu, Zhiguo Xie, Kefeng Shen, Lizhu Jiang, Chongyan Liu, Yongsheng Ge, Jihai Yu, Weidong Jia, Jinliang Ma, Hao Chen

Original Paper

CD4 T cells in chronic myeloid leukemia present MHC class II-dependent and IFN-γ-dependent cytotoxic capacity

Yirong Jiang, Jingwei Yao, Zhuoxin Yao, Yueting Huang, Zhangkun Li, Ziying Fan, Yong Zhou, Guowei Li, Zhifeng Li, Bing Xu

Original Paper

Advanced nano-therapeutic delivery of metformin: potential anti-cancer effect against human colon cancer cells through inhibition of GPR75 expression

Fatemeh Ghorbanzadeh, Davoud Jafari-Gharabaghlou, Mohammad Reza Dashti, Mehrdad Hashemi, Nosratollah Zarghami

Original Paper

The anticancer effects of thymol on HepG2 cell line

Fatih Altintas, Melek Tunc-Ata, Mucahit Secme, Vural Kucukatay

Original Paper

EGCG attenuate EGF triggered matrix abundance and migration in HPV positive and HPV negative cervical cancer cells

Rajalakshmi Sabanayagam, Sneha Krishnamoorthy, Jayapradha Gnanagurusamy, Bharathi Muruganatham, Sridhar Muthusami

Original Paper

Artichoke as a melanoma growth inhibitor

Annette M. Mathew, Zuliang Deng, Christian J. Nelson, Trenton G. Mayberry, Qian Bai, Marco Lequio, Emerson Fajardo, Huaping Xiao, Mark R. Wakefield, Yujiang Fang

Original Paper

Concomitant effects of paclitaxel and celecoxib on genes involved in apoptosis of triple-negative metastatic breast cancer cells

Mohaddeseh Hedayat, Mohammad Rafi Khezri, Reza Jafari, Hassan Malekinejad, Naime Majidi Zolbanin

Original Paper

6-Methoxydihydrosanguinarine exhibits cytotoxicity and sensitizes TRAIL-induced apoptosis of hepatocellular carcinoma cells through ROS-mediated upregulation of DR5

Lin-lin Wang, Ruo-tong Li, Zi-heng Zang, Yun-xuan Song, Yu-zhe Zhang, Teng-fei Zhang, Feng-ze Wang, Gang-ping Hao, Lu Cao

Original Paper

CRISPR screen identifies GATAD1 as a synthetic lethal target with CDK4/6 inhibitors in estrogen receptor-positive breast cancer

Wenqiang Liu, Ruhua Zhang, Xinhao Yu, Yu Zhang, Tiebang Kang, Dan Liao

Original Paper

Claudin-3 facilitates the progression and mediates the tumorigenic effects of TGF-β in glioblastoma multiforme

Zhiqiang Sun, Tengfeng Yan, Hongxiang Jiang, Jiayang Cai, Xiwei Zhu, Qianxue Chen

Original Paper

Mechanism of anticancer effect of gambogic acid on gastric signet ring cell carcinoma

Ziad Joha, Ayşegül Öztürk, Fatih Yulak, Özhan Karataş, Hilmi Ataseven

Original Paper

The Schiff base hydrazine copper(II) complexes induce apoptosis by P53 overexpression and prevent cell migration through protease-independent pathways

Vahid Asghariazar, Mohammad Amini, Zahra Pirdel, Roghayeh Fekri, Asadollah Asadi, Kazem Nejati-Koshki, Behzad Baradaran, Yasin Panahi

Original Paper

METTL3 regulatory TROAP can regulate the progression of non-small cell lung cancer through PI3K/AKT and EMT signaling pathway

Muli Xu, Jiankun Yu, Xiaoxiao Liu, Wanting Jia, Yu Duan, Di Ma, Jiaxuan Ma, Wanyang Lei, Wenlin Tai

Original Paper

The mechanism of LSM2 in the progression of live hepatocellular carcinoma was analyzed based on bioinformatics

Peifang Qin, Haitao Huang, Jiahui Wang, Tingting Jiang, Nannan Zeng, Qi Wang, Yulin He, Yali Zhou

Review Article

The mechanistic insights of the antioxidant Keap1-Nrf2 pathway in oncogenesis: a deadly scenario

Anirban Goutam Mukherjee, Abilash Valsala Gopalakrishnan

Review Article

Current neoadjuvant therapy for operable locally advanced esophageal cancer

Wenwei Yang, Yaru Niu, Yongkun Sun

Review Article

Exosomal non-coding RNAs-mediated EGFR-TKIs resistance in NSCLC with EGFR mutation

Daoan Cheng, Banglu Wang, Lige Wu, Rui Chen, Weiqing Zhao, Cheng Fang, Mei Ji

Review Article

Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer

Lu Zhang, Zhi Li, Meng Zhang, Huangren Zou, Yuke Bai, Yanlin Liu, Juan Lv, Ling Lv, Pengjie Liu, Zhiyong Deng, Chao Liu

Review Article

Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role

Sandra Kannampuzha, Abilash Valsala Gopalakrishnan

Review Article

Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis

Farzaneh Karimi, Omid Azadbakht, Ali Veisi, Mohammad Sabaghan, Maryam Owjfard, Ebrahim Kharazinejad, Negar Dinarvand

Review Article

The potential of monoclonal antibodies for colorectal cancer therapy

Fatemeh Heidari, Soheil Madadi, Neda Alizadeh, Mohammad Hossein Alimardani, Armin Safari, Mohammad Hossein Armand, Elahe Pishgahzadeh, Meysam Soleimani

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.